Charles River Laboratories Intl. Inc vs Vale SA — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Vale SA trades at $13.6 (market cap $57.32B). The key difference: Vale SA is far larger — about 4× Charles River Laboratories Intl. Inc's market cap, and Vale SA pays a 8.87% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Vale SA for 109 Days on average.
| CRL | VALE | |
|---|---|---|
Market Cap | $14.23B | $57.32B |
Volume | 1,176,885 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $310.77 | $17.82 |
52-Week Low | $149.93 | $10.75 |
Typical Hold Time | 33 Days | 109 Days |
Enterprise Value | $17.06B | $73.56B |
Dividend Yield | — | 8.87% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
VALE trades at $13.61, down 3.34% amid broader market weakness in mining stocks. The stock shows bearish technical signals with recent earnings misses and declining profit margins (5.11% net margin in 2025). Revenue has stabilized around $38-41B, but iron ore pricing pressure and rising costs challenge near-term profitability. Analyst consensus remains mixed with 32% buy ratings despite a $16.21 price target suggesting 19% upside potential.
The investment case balances Vale's position as a low-cost iron ore producer against cyclical commodity exposure and Brazilian regulatory risks. Base metals growth provides diversification, but margin compression and debt increases warrant caution. Current valuation at 27x P/E appears stretched given earnings volatility, making risk-reward balanced for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →